Market Cap | 430.17M | P/E | - | EPS this Y | -94.40% | Ern Qtrly Grth | - |
Income | -73.48M | Forward P/E | -3.61 | EPS next Y | 4.80% | 50D Avg Chg | 9.00% |
Sales | 110.5M | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -39.00% |
Recommedations | 2.00 | Quick Ratio | 0.90 | Shares Outstanding | 152.09M | 52W Low Chg | 86.00% |
Insider Own | 13.93% | ROA | -23.84% | Shares Float | 65.77M | Beta | -1.13 |
Inst Own | 64.71% | ROE | - | Shares Shorted/Prior | 3.53M/3.35M | Price | 4.37 |
Gross Margin | -26.30% | Profit Margin | -66.50% | Avg. Volume | 441,150 | Target Price | 14.89 |
Oper. Margin | -177.72% | Earnings Date | Nov 7 | Volume | 287,782 | Change | 0.00% |
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Jones Trading | Buy | Sep 25, 24 |
HC Wainwright & Co. | Buy | Sep 25, 24 |
B. Riley Securities | Buy | Sep 19, 24 |
JP Morgan | Overweight | Sep 9, 24 |
Jones Trading | Buy | Aug 9, 24 |
HC Wainwright & Co. | Buy | Jun 26, 24 |
Mizuho | Outperform | Jun 25, 24 |
Wells Fargo | Overweight | May 15, 24 |
Truist Securities | Buy | Apr 1, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. | Director Director | Dec 11 | Buy | 5.00 | 1,000,000 | 5,000,000 | 18,202,009 | 01/17/24 |
Moran Kyle | Chief Financial Offi.. Chief Financial Officer | Aug 23 | Sell | 4.752 | 37,062 | 176,119 | 46,120 | 08/23/23 |
Vargeese Chandra | See Remarks See Remarks | Feb 16 | Sell | 4.03 | 10,249 | 41,303 | 106,624 | 02/17/23 |
BOLNO PAUL | President and CEO President and CEO | Feb 16 | Sell | 4.04 | 29,400 | 118,776 | 407,425 | 02/17/23 |
Francis Chris | See Remarks See Remarks | Feb 16 | Sell | 4.03 | 10,258 | 41,340 | 79,714 | 02/17/23 |
Moran Kyle | Chief Financial Offi.. Chief Financial Officer | Feb 16 | Sell | 4.04 | 9,729 | 39,305 | 79,751 | 02/17/23 |
Vargeese Chandra | See Remarks See Remarks | May 04 | Sell | 1.72 | 16,714 | 28,748 | 111,095 | 05/06/22 |
BOLNO PAUL | President and CEO President and CEO | May 04 | Sell | 1.72 | 33,501 | 57,622 | 436,825 | 05/06/22 |
Moran Kyle | Chief Financial Offi.. Chief Financial Officer | May 04 | Sell | 1.72 | 5,021 | 8,636 | 84,567 | 05/06/22 |
Panzara Michael A. | See Remarks See Remarks | May 04 | Sell | 1.72 | 16,714 | 28,748 | 109,103 | 05/06/22 |
Francis Chris | See Remarks See Remarks | May 04 | Sell | 1.72 | 10,867 | 18,691 | 89,972 | 05/06/22 |
Moran Kyle | Chief Financial Offi.. Chief Financial Officer | Feb 16 | Sell | 2.31 | 9,204 | 21,261 | 74,588 | 02/18/22 |
Francis Chris | See Remarks See Remarks | Feb 16 | Sell | 2.31 | 10,123 | 23,384 | 68,339 | 02/18/22 |
Vargeese Chandra | Chief Technology Off.. Chief Technology Officer | Feb 16 | Sell | 2.32 | 10,603 | 24,599 | 77,809 | 02/18/22 |
BOLNO PAUL | President and CEO President and CEO | Feb 16 | Sell | 2.32 | 33,150 | 76,908 | 377,826 | 02/18/22 |
Panzara Michael A. | See Remarks See Remarks | Feb 16 | Sell | 2.31 | 10,603 | 24,493 | 75,817 | 02/18/22 |
BOLNO PAUL | President and CEO President and CEO | Feb 18 | Sell | 10.57 | 11,205 | 118,437 | 410,976 | 02/18/21 |
Panzara Michael A. | See Remarks See Remarks | Feb 18 | Sell | 10.57 | 2,929 | 30,960 | 86,420 | 02/18/21 |
BOLNO PAUL | President and CEO President and CEO | Sep 17 | Option | 2.48 | 100,000 | 248,000 | 372,181 | 09/17/20 |
BOLNO PAUL | President and CEO President and CEO | Sep 17 | Sell | 15 | 100,000 | 1,500,000 | 272,181 | 09/17/20 |